Alnylam shares positive results from phase 1 trial

Betsy Goodfellow | July 17, 2023 | News story | Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial 

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of ALN-APP. The drug is an investigational RNAi therapy, which targets amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA).

Results from part A of the trial were presented at the 2023 Alzheimer’s Association International Conference (AAIC) which is being held on the 16-20 July, 2023 in Amsterdam, the Netherlands. The drug is being developed as part of a collaboration between Alnylam and Regeneron Pharmaceuticals.

The trial has enrolled 20 patients in the phase 1 portion of the trial, assessing single doses of ALN-APP administered via intrathecal injection, which have so far been well tolerated, with only mild or moderate adverse events having been reported.

Patients who received a single 75mg dose of ALN-APP experienced a rapid and sustained reduction in cerebrospinal fluid of both soluble APPα and soluble APPβ, both of which are biomarkers of target engagement. The maximum reductions of these biomarkers were 84% and 90%, respectively.

The company is intending to initiate part B of this trial, which would be a multiple-dose trial, likely enrolling some of the patients from part A.

Dr Sharon Cohen, MD FRCPC, neurologist and medical director at the Toronto Memory Program, commented: “We’ve known for decades that mutations that increase APP production, or alter its proteolysis, cause early-onset Alzheimer’s disease, early-onset CAA or both. These phase 1 results show that a single dose of ALN-APP can rapidly reduce APP production and that this effect is sustained at six months. Given the critical need for new and better treatments for AD and CAA, these results are promising, and the approach warrants further study.”

Tim Mooney, director and ALN-APP programme leader at Alnylam, added: “The rapid, robust and sustained target engagement we have achieved with a single dose of ALN-APP and the encouraging interim safety data to date illustrate the potential of RNAi therapeutics to set a new standard for silencing disease-causing genes in the central nervous system and target diseases like AD and CAA upstream of existing therapies. We are excited to initiate the multiple dose part of the phase 1 study and learn more about the potential of this new approach for these devastating diseases.”

Betsy Goodfellow

Related Content

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

Latest content